Hani Salehi-Had, MD
Retina Specialist · Huntington Beach, CANPI 1306909403
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,592 of the $22,894 with a category attached, or 68.1%. 25 manufacturers reported payments, led by Regeneron at 44.8% of the total. Reporting peaked in 2024 at $7,672 and has fallen 74.3% since, to $1,971 in 2025.
Across 178 payments — averaging $128.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$10K
- AbbVie$4K
- Boehringer Ingelheim$3K
- Regeneron Healthcare Solutions, Inc.$903
- Apellis Pharmaceuticals, Inc.$751
- Alcon$745
- plus $3K from 19 others
Across 1,141 payments — averaging $10,640 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$9.1M
- Regeneron$1.8M
- Apellis Pharmaceuticals, Inc.$249K
- Kyowa Kirin, Inc.$239K
- Eyepoint US, Inc.$237K
- Boehringer Ingelheim International GmbH$157K
- plus $391K from 9 others
What the payments were for
- Consulting fees$15,59268%
- Travel & lodging$4772%
- Food & beverage$6,80530%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 16 | $10,259 |
| AbbVie(2 entities) | 25 | $3,638 |
| Boehringer Ingelheim | 4 | $3,391 |
| Regeneron Healthcare Solutions, Inc. | 19 | $903 |
| Apellis Pharmaceuticals, Inc. | 16 | $751 |
| Alcon | 8 | $745 |
| Genentech USA, Inc. | 14 | $542 |
| Novartis | 12 | $526 |
| Sun Pharmaceutical Industries Inc. | 9 | $446 |
| Astellas Pharma US Inc | 22 | $411 |
| Astellas Pharma Global Development | 5 | $220 |
| Alimera Sciences, Inc. | 3 | $212 |
| Genentech, Inc. | 5 | $187 |
| Harrow Eye, LLC | 2 | $152 |
| Ocular Therapeutix, Inc. | 3 | $126 |
| Bausch & Lomb Americas Inc. | 4 | $100 |
| Coherus Oncology, Inc. | 2 | $66 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $34 |
| Dompe US, Inc. | 1 | $34 |
| Amgen | 1 | $23 |
| Eyepoint US, Inc. | 1 | $23 |
| Lumibird Medical Inc. | 1 | $23 |
| Spark Therapeutics, Inc. | 1 | $21 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,894 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 90 | $37,052 |
| Alphagan PBrimonidine Tartrate | 48 | $20,026 |
| XiidraLifitegrast | 17 | $15,386 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $12,148 |
| RhopressaNetarsudil Mesylate | 36 | $11,654 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $10,531 |
| Prednisolone Acetate | 187 | $8,169 |
| Brimonidine Tartrate | 140 | $7,633 |
| Restasis MultidoseCyclosporine | 11 | $6,902 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,681 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 60 | $6,080 |
| Ketorolac Tromethamine | 210 | $3,025 |
| Acetazolamide | 34 | $2,946 |
| Brinzolamide | 18 | $2,769 |
| Cyclosporine | 11 | $2,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis Multidose | $3,638 | $76,129186 claims |
| Bausch & Lomb Americas Inc.Xiidra | $100 | $15,38617 claims |
| AlconSimbrinza | $745 | $10,53145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 retina specialist providers in California.
Other retina specialist in Huntington Beach
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
- Diana DoStanford$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.